157 related articles for article (PubMed ID: 21731703)
1. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
Yin L; Rao P; Elson P; Wang J; Ittmann M; Heston WD
PLoS One; 2011; 6(6):e21319. PubMed ID: 21731703
[TBL] [Abstract][Full Text] [Related]
2. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
Semaan L; Mander N; Cher ML; Chinni SR
BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
[TBL] [Abstract][Full Text] [Related]
3. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.
Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A
BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414
[TBL] [Abstract][Full Text] [Related]
4. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
[TBL] [Abstract][Full Text] [Related]
5. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.
Washington MN; Weigel NL
Endocrinology; 2010 Apr; 151(4):1409-17. PubMed ID: 20147525
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
Cai C; Wang H; Xu Y; Chen S; Balk SP
Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279
[TBL] [Abstract][Full Text] [Related]
7. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
[TBL] [Abstract][Full Text] [Related]
8. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
Urbinati G; Ali HM; Rousseau Q; Chapuis H; Desmaële D; Couvreur P; Massaad-Massade L
PLoS One; 2015; 10(5):e0125277. PubMed ID: 25933120
[TBL] [Abstract][Full Text] [Related]
9. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
10. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
11. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.
Mani RS; Iyer MK; Cao Q; Brenner JC; Wang L; Ghosh A; Cao X; Lonigro RJ; Tomlins SA; Varambally S; Chinnaiyan AM
Cancer Res; 2011 Aug; 71(16):5387-92. PubMed ID: 21676887
[TBL] [Abstract][Full Text] [Related]
12. Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.
Bonaccorsi L; Nesi G; Nuti F; Paglierani M; Krausz C; Masieri L; Serni S; Proietti-Pannunzi L; Fang Y; Jhanwar SC; Orlando C; Carini M; Forti G; Baldi E; Luzzatto L
J Endocrinol Invest; 2009 Jul; 32(7):590-6. PubMed ID: 19494719
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
14. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1.
Liu B; Gu X; Huang T; Luan Y; Ding X
Oncol Rep; 2017 Jan; 37(1):201-208. PubMed ID: 28004109
[TBL] [Abstract][Full Text] [Related]
15. Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells.
Cai J; Kandagatla P; Singareddy R; Kropinski A; Sheng S; Cher ML; Chinni SR
Transl Oncol; 2010 Jun; 3(3):195-203. PubMed ID: 20563261
[TBL] [Abstract][Full Text] [Related]
16. Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.
He J; Sun X; Shi T; Schepmoes AA; Fillmore TL; Petyuk VA; Xie F; Zhao R; Gritsenko MA; Yang F; Kitabayashi N; Chae SS; Rubin MA; Siddiqui J; Wei JT; Chinnaiyan AM; Qian WJ; Smith RD; Kagan J; Srivastava S; Rodland KD; Liu T; Camp DG
Mol Oncol; 2014 Oct; 8(7):1169-80. PubMed ID: 25266362
[TBL] [Abstract][Full Text] [Related]
17. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.
Bastus NC; Boyd LK; Mao X; Stankiewicz E; Kudahetti SC; Oliver RT; Berney DM; Lu YJ
Cancer Res; 2010 Dec; 70(23):9544-8. PubMed ID: 20947519
[TBL] [Abstract][Full Text] [Related]
18. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
19. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
[TBL] [Abstract][Full Text] [Related]
20. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
Shao L; Kahraman N; Yan G; Wang J; Ozpolat B; Ittmann M
Prostate; 2020 Jan; 80(1):65-73. PubMed ID: 31614005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
